CSIMarket
 
Axogen inc   (AXGN)
Other Ticker:  
 
 
Price: $13.7900 $0.22 1.621%
Day's High: $13.81 Week Perf: 5.91 %
Day's Low: $ 13.53 30 Day Perf: 28.28 %
Volume (M): 209 52 Wk High: $ 13.81
Volume (M$): $ 2,888 52 Wk Avg: $7.72
Open: $13.66 52 Wk Low: $3.45



 Market Capitalization (Millions $) 603
 Shares Outstanding (Millions) 44
 Employees 584
 Revenues (TTM) (Millions $) 169
 Net Income (TTM) (Millions $) -19
 Cash Flow (TTM) (Millions $) 11
 Capital Exp. (TTM) (Millions $) 11

Axogen Inc
Axogen, Inc. is a company that develops and markets innovative surgical solutions for peripheral nerve injuries. The company was founded in 2002 and is headquartered in Alachua, Florida. Axogen's mission is to provide surgeons with products and techniques that will allow them to precisely repair or replace damaged peripheral nerves to restore function.

Axogen has a portfolio of products that includes nerve grafts, nerve connectors, and platforms that are designed to facilitate the surgical repair of nerves. Some of Axogen's key products include:

1. Avance Nerve Graft e a processed human nerve allograft that is used to bridge gaps in damaged peripheral nerves.

2. Axoguard Nerve Connector e a collagen scaffold for connecting two severed peripheral nerves.

3. Axotouch Two-Point Discriminator e a handheld device for testing the sensitivity of nerves.

In addition to its product portfolio, Axogen is also focused on developing new technologies and techniques for nerve repair. The company has an active research and development program and partners with leading academic and clinical institutions to advance the field of peripheral nerve repair.

Axogen's products are used in a variety of surgical procedures, including reconstruction after trauma or tumor removal, as well as in the treatment of chronic conditions such as carpal tunnel syndrome and diabetic neuropathy.

Axogen has a strong track record of growth and profitability, with revenues reaching $171 million in 2020. The company has a market capitalization of over $2 billion and is listed on the NASDAQ Global Select Market.

Overall, Axogen is a leading company in the field of peripheral nerve repair and has established itself as a key player in this growing market. Its innovative products and commitment to research and development make it well-positioned for continued success in the coming years.


   Company Address: 13631 Progress Blvd Alachua, 32615 FL
   Company Phone Number: 462-6800   Stock Exchange / Ticker: NASDAQ AXGN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Management Announcement

Axogen Inc's Inducement Grant Amidst Financial Struggles and Competitive Setbacks

Published Mon, Jul 1 2024 11:00 AM UTC



Axogen Inc, a global leader in surgical solutions for peripheral nerve injuries, recently reported an inducement grant made under NASDAQ listing rule 5635(c)(4) in connection with the hiring of a new non-executive employee. This news comes at a time when the company recorded a cumulative net loss of $24 million and experienced a decline in its return on assets with...

Product Service News

Axogen, Inc. Drives Innovation with the Launch of Avive+ Soft Tissue Matrix

Published Mon, Jun 24 2024 11:00 AM UTC

In a groundbreaking move, Axogen, Inc., a leading player in the field of innovative surgical solutions for peripheral nerve injuries, has recently announced the full launch of their newest product, Avive+ Soft Tissue Matrix. This resorbable, multi-layer amniotic membrane allograft is designed to act as a soft tissue barrier, offering temporary protection and tissue separatio...

Management Announcement

Axogen Inc. Initiates Rolling Submission of Biologics License Application for Avance Nerve Graft to U.S. FDA, Boosting Investor Confidence with 1.41% Rise in Stock

Published Thu, May 16 2024 11:01 AM UTC



Alachua, Fla. and Tampa, Fla., May 16, 2024 - Axogen Inc. (NASDAQ: AXGN), a recognized global leader in the development and marketing of innovative surgical solutions for peripheral nerve injuries, is proud to announce the commencement of the rolling submission process for a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for li...

Product Service News

Axogen Achieves First Surgical Implants Milestone with Avive+ Soft Tissue Matrix: A New Era in Peripheral Nerve Injuries Treatment

Published Mon, Apr 29 2024 8:50 PM UTC

Axogen, Inc., the well-known global leader in the development and marketing of innovative surgical solutions for peripheral nerve injuries, recently announced the execution of the first surgical implantations using its newest product, Avive+ Soft Tissue Matrix. This significant development was reported in Tampa and Alachua, Florida, on April 29, 2024.The Avive+ Soft Tissue M...

Shares

Axogen, Inc. Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) for New Area Vice President of Sales

Published Fri, Feb 2 2024 9:15 PM UTC



Axogen, Inc. (NASDAQ: AXGN), a renowned global leader in the development and marketing of innovative surgical solutions for peripheral nerve injuries, recently made an important announcement regarding inducement grants under NASDAQ Listing Rule 5635(c)(4). These grants were made in connection with the appointment of John Manning as the new Area Vice President of Sa...







Axogen Inc's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com